Astex Pharmaceuticals Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Astex Pharmaceuticals Ltd.
The UK big pharma gets a first-in-class approval in breast cancer, but a challenger is emerging.
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
Twelve applications with September goal dates include six novel agents but only one breakthrough designation.
The company posted positive topline results from the Phase III MVOR-1 and MVOR-2 trials comparing DFD-29 against Galderma’s drug in papulopustular rosacea.
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.